6/22/2023 0 Comments New migraine medication![]() Since 2019, 2 new classes of medications have become available with an alternative MOA to triptans: gepants- small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, including ubrogepant (Ubrelvy AbbVie) and rimegepant (Nurtec ODT Biohaven Pharmaceutical Holding Company Ltd) and ditans-5-HT1F agonists. Updates in Acute Migraine Medications Gepants and ditans In this article, we will highlight new therapeutic options for both acute and preventive treatment of migraine and discuss their use versus traditional therapies. Recognizing that new treatments require some general agreement around their use vs what was considered standard of care, the American Headache Society published an updated consensus statement in 2021 focused on assisting clinicians in when to consider new acute and preventative medications or neuromodulation for patients with migraine. Add to that the complexity of constant insurance hurdles and the fact that excitement about innovative products can wane as the fatigue associated with prior authorizations mounts-resulting in delays in getting your patient appropriate care becoming standard. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma. Newer preventive treatments bring the first migraine-specific pharmacologic preventives to the field.Īlthough new treatments and innovations are a sign of growth in the field, it is important to realize that growth comes with a certain amount of pain. Newer acute treatments can address unmet patient needs by providing nonoral formulations, reduced adverse effects, eliminated risk of medication-overuse headache, different modes and mechanisms of action, and reduced contraindications. ![]() This targeted MOA comes with a reduction in adverse effects, resulting in greater tolerability, increased ability for patients to remain on treatment, and improved long-term results. 1,2 The new wave of therapeutics have a targeted mechanism of action (MOA) based on migraine pathophysiology. Traditional migraine treatments are most often discontinued by patients and clinicians due to lack of efficacy and poor tolerability. Although clinicians now have plenty of options, it can be difficult to choose between them and understand how novel treatments compare with traditional therapies. During the past 5 years, several new treatments, both preventive and acute, have become available. Thus, the importance of effective strategies for managing this disease could not be more paramount. ![]() MIGRAINE IS A CHRONIC and often debilitating disease affecting 1 in 7 individuals globally and one of the top 20 causes of disability worldwide. ![]()
0 Comments
Leave a Reply. |